Financial Statement Details (Tables)

3 Months Ended

Mar. 31, 2016

Disclosure of Financial Statement Details [Abstract]

Financial Statement Details

3. Financial Statement Details (in millions)

Short- Term Marketable Securities, Available-for-Sale

Short-term marketable securities, consisting solely of debt securities, were as follows:

	March 31, 2016
	Amortized Cost		Gross Unrealized Gains		Gross Unrealized Losses		Estimated Market Value
U.S. government agencies	$	22.8	$	—	$	—	$	22.8
Corporate debt	4.3		—		—		4.3
Commercial paper	1.5		—		—		1.5
Total	$	28.6	$	—	$	—	$	28.6

	December 31, 2015
	Amortized Cost		Gross Unrealized Gains		Gross Unrealized Losses		Estimated Market Value
U.S. government agencies	$	22.1	$	—	$	—	$	22.1
Corporate debt	4.9		—		—		4.9
Commercial paper	2.1		—		—		2.1
Total	$	29.1	$	—	$	—	$	29.1

As of March 31, 2016, the estimated market value of available-for-sale marketable securities with contractual maturities of up to one year and up to two years were $24.8 million and $3.8 million, respectively.

Inventory

	March 31, 2016		December 31, 2015
Raw materials	$	23.4	$	16.0
Work-in-process	2.9		2.6
Finished goods	19.8		16.6
Total	$	46.1	$	35.2

Accounts Payable and Accrued Liabilities

	March 31, 2016		December 31, 2015
Accounts payable trade	$	21.5	$	19.0
Accrued tax, audit, and legal fees	2.9		2.1
Clinical trials	0.4		0.7
Accrued other including warranty	20.3		17.1
Total	$	45.1	$	38.9

Accrued Warranty

Warranty costs are reflected in the consolidated statements of operations as product cost of sales. A reconciliation of our accrued warranty costs for the three months ended March 31, 2016 and 2015 were as follows:

	Three Months Ended   March 31,
	2016			2015
Beginning balance	$	3.3		$	1.3
Charges to costs and expenses	6.2			1.2
Costs incurred	(3.8		)	(1.4		)
Ending balance	$	5.7		$	1.1

Short Term Marketable Securities, Available for Sale

Short- Term Marketable Securities, Available-for-Sale

Short-term marketable securities, consisting solely of debt securities, were as follows:

	March 31, 2016
	Amortized Cost		Gross Unrealized Gains		Gross Unrealized Losses		Estimated Market Value
U.S. government agencies	$	22.8	$	—	$	—	$	22.8
Corporate debt	4.3		—		—		4.3
Commercial paper	1.5		—		—		1.5
Total	$	28.6	$	—	$	—	$	28.6

	December 31, 2015
	Amortized Cost		Gross Unrealized Gains		Gross Unrealized Losses		Estimated Market Value
U.S. government agencies	$	22.1	$	—	$	—	$	22.1
Corporate debt	4.9		—		—		4.9
Commercial paper	2.1		—		—		2.1
Total	$	29.1	$	—	$	—	$	29.1

As of March 31, 2016, the estimated market value of available-for-sale marketable securities with contractual maturities of up to one year and up to two years were $24.8 million and $3.8 million, respectively.

Inventory

Inventory

	March 31, 2016		December 31, 2015
Raw materials	$	23.4	$	16.0
Work-in-process	2.9		2.6
Finished goods	19.8		16.6
Total	$	46.1	$	35.2

Accounts Payable and Accrued Liabilities

Accounts Payable and Accrued Liabilities

	March 31, 2016		December 31, 2015
Accounts payable trade	$	21.5	$	19.0
Accrued tax, audit, and legal fees	2.9		2.1
Clinical trials	0.4		0.7
Accrued other including warranty	20.3		17.1
Total	$	45.1	$	38.9

Accrued Warranty

Accrued Warranty

Warranty costs are reflected in the consolidated statements of operations as product cost of sales. A reconciliation of our accrued warranty costs for the three months ended March 31, 2016 and 2015 were as follows:

	Three Months Ended   March 31,
	2016			2015
Beginning balance	$	3.3		$	1.3
Charges to costs and expenses	6.2			1.2
Costs incurred	(3.8		)	(1.4		)
Ending balance	$	5.7		$	1.1